Latest filings (excl ownership)
15-12B
Securities registration termination
13 Aug 21
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9 Aug 21
25-NSE
Exchange delisting
3 Aug 21
425
Business combination disclosure
29 Jul 21
8-K
Intec Announces $30 Million Private Placement Ahead of Decoy Merger
29 Jul 21
425
Business combination disclosure
23 Jul 21
8-K
Other Events
23 Jul 21
425
Business combination disclosure
16 Jul 21
8-K
Other Events
16 Jul 21
425
Business combination disclosure
22 Jun 21
8-K
Submission of Matters to a Vote of Security Holders
22 Jun 21
10-Q
2021 Q1
Quarterly report
17 May 21
DEFM14A
Proxy related to merger
14 May 21
EFFECT
Notice of effectiveness
14 May 21
CORRESP
Correspondence with SEC
13 May 21
425
Business combination disclosure
30 Apr 21
8-K
Entry into a Material Definitive Agreement
30 Apr 21
UPLOAD
Letter from SEC
22 Apr 21
S-4
Registration of securities issued in business combination transactions
20 Apr 21
10-K/A
2020 FY
Annual report (amended)
17 Mar 21
10-K
2020 FY
Annual report
16 Mar 21
8-K
Intec Pharma and Decoy Biosystems Announce Merger Agreement
15 Mar 21
425
Business combination disclosure
15 Mar 21
8-K
Departure of Directors or Certain Officers
8 Feb 21
8-K
Intec Pharma Announces Cannabinoid Research Collaboration with GW Pharma
9 Dec 20
10-Q
2020 Q3
Quarterly report
5 Nov 20
8-K
Intec Pharma Reports Third Quarter 2020 Financial Results and Provides Corporate Update
5 Nov 20
8-K
Intec Pharma Announces 1-for-20 Reverse Share Split
29 Oct 20
8-K
Intec Pharma Announces New Research Collaboration Agreement with MSD
8 Oct 20
8-K
Departure of Directors or Certain Officers
2 Oct 20
8-K
Departure of Directors or Certain Officers
18 Sep 20
S-8
Registration of securities for employees
17 Aug 20
424B5
Prospectus supplement for primary offering
10 Aug 20
8-K
Intec Pharma Announces Pricing of $4.9 Million Registered Direct Offering
10 Aug 20
10-Q
2020 Q2
Quarterly report
5 Aug 20
8-K
Intec Pharma Reports Second Quarter 2020 Financial Results and Provides Corporate Update
5 Aug 20
8-K
Departure of Directors or Certain Officers
17 Jul 20
EFFECT
Notice of effectiveness
17 Jun 20
424B3
Prospectus supplement
16 Jun 20
Latest ownership filings
SC 13G/A
CVI Investments, Inc.
16 Feb 21
SC 13G/A
INTRACOASTAL CAPITAL, LLC
29 Jan 21
SC 13G/A
SABBY MANAGEMENT, LLC
4 Jan 21
SC 13G/A
MEITAV DASH INVESTMENTS LTD
4 Nov 20
4
Nir Sassi
18 Sep 20
4
Walt Addison Linscott
18 Sep 20
4
Nadav Navon
18 Sep 20
4
Roger Pomerantz
17 Jul 20
4
Jeffrey A Meckler
17 Jul 20
4
ANTHONY J MADDALUNA
17 Jul 20
4
Hila Karah
17 Jul 20
4
William B Hayes
17 Jul 20
4
JOHN W KOZARICH
17 Jul 20
SC 13G
ARMISTICE CAPITAL, LLC
14 May 20
SC 13G
CVI Investments, Inc.
13 May 20
SC 13G/A
Intec Pharma Ltd.
25 Feb 20
4
Nir Sassi
19 Feb 20
4
Nadav Navon
19 Feb 20
4
Walt Addison Linscott
19 Feb 20
4
R MICHAEL GENDREAU
19 Feb 20
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G/A
Beneficial ownership report (amended)
12 Feb 20
SC 13G/A
Beneficial ownership report (amended)
12 Feb 20
SC 13G
Intec Pharma Ltd.
11 Feb 20
SC 13G
Beneficial ownership report
7 Feb 20
SC 13G
Beneficial ownership report
5 Feb 20
SC 13G/A
Intec Pharma Ltd.
5 Feb 20
4
Dan Oren
4 Feb 20
4
Issac Silberman
21 Nov 19
4
Nir Sassi
16 Sep 19
4
Walt Addison Linscott
16 Sep 19
4
Jeffrey A Meckler
29 Aug 19
4
ANTHONY J MADDALUNA
29 Aug 19
4
JOHN W KOZARICH
27 Aug 19
4
Jeffrey A Meckler
27 Aug 19
4
Issac Silberman
2 Jul 19
4
Roger Pomerantz
2 Jul 19
4
ANTHONY J MADDALUNA
2 Jul 19
4
Hila Karah
2 Jul 19
4
William B Hayes
2 Jul 19